Daiwa released a research report stating that WUXI BIO (02269) and WuXi XDC (02268) announced they will make a general offer to acquire at least 60% of the shares of BIODLINK-B (01875) for a maximum consideration of approximately 2.8 billion yuan, with expectations that BIODLINK-B will maintain its listing status post-completion. WuXi XDC anticipates that this acquisition will aid in business expansion, secure additional operational production capacity in China, further enrich its project portfolio, broaden its client base, and consolidate its leading market position in the ADC contract development and manufacturing organization (CDMO) sector. Daiwa currently assigns an investment rating of "Buy" to WUXI BIO.